Similar articles

• A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.

  Villeneuve A, Pires A, Jus A, Lachance R, Drolet A. Villeneuve A, et al. Curr Ther Res Clin Exp. 1972 Nov;14(11):696-706. Curr Ther Res Clin Exp. 1972. PMID: 4404626 No abstract available.
• Clinical experience with pipotiazine palmitate (19.552 R.P.) in Nordic countries. Report of a multicentre investigation.

  Kristjansen P, Dencker SJ, Elley J, Hakola A, Heshe J, Malm U, Robak OH, Salvesen C, Vaksdal K. Kristjansen P, et al. Acta Psychiatr Scand Suppl. 1973;241:51-6. doi: 10.1111/j.1600-0447.1973.tb07042.x. Acta Psychiatr Scand Suppl. 1973. PMID: 4147511 Clinical Trial. No abstract available.
• Pipotiazine palmitate (19.552 R.P.) in the long-term treatment of chronic psychoses. A controlled trial on in-patients.

  Robak OH. Robak OH. Acta Psychiatr Scand Suppl. 1973;241:83-94. doi: 10.1111/j.1600-0447.1973.tb07046.x. Acta Psychiatr Scand Suppl. 1973. PMID: 4147515 Clinical Trial. No abstract available.
• Risperidone: integrating research and practice.

  Addington D. Addington D. Br J Hosp Med. 1994 Sep 7-20;52(5):223-4. Br J Hosp Med. 1994. PMID: 7529628 Review.
• Pimavanserin: First Global Approval.

  Markham A. Markham A. Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9. Drugs. 2016. PMID: 27262680 Review.